Clinical Oncology NewsBrentuximab Vedotin Gets New Indication

The approval for the treatment of pediatric patients aged 2 years and older with previously untreated high-risk classic Hodgkin lymphoma (HL) was based on the AHOD1331 phase 3 study, which examined the effects of brentuximab vedotin (Adcetris, Seagen) in combination with the dose-intensive chemotherapy regimen AVE-PC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide). Results showed that patients who received the AVE-PC combination had better event-free survival than those who received ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide). Patients experienced a 59% decrease in their risk of death, second cancer, or disease progression.